May 18, 2021 / 01:45PM GMT
Luca Issi - RBC Capital Markets, Research Division - Research Analyst
Great. Hello, everybody, and thank you for dialing in. My name is Luca Issi. I'm a senior biotech analyst here at RBC Capital Market. And today, it's our great privilege to have Sandy Macrae, CEO of Sangamo, for a fireside chat. Sandy, thanks so much for joining us today.
Questions and Answers:
Luca Issi - RBC Capital Markets, Research Division - Research AnalystAnd maybe before we dive into the specifics, we'll love if you can share your thoughts on your platform. It feels to me that these days, all the headlines are on CRISPR/Cas9. But maybe can you talk about your zinc finger protease platform and some of the differentiating features versus CRISPR/Cas9?
Alexander D. Macrae - Sangamo Therapeutics, Inc. - CEO, President & Director
Delighted to, and good morning. It's a privilege to lead Sangamo and a truly remarkable platform. Zinc fingers are the most common transcription factors in our body. And through its years of expertise, Sangamo
Trustpilot
